Employer Action Playbook

This page reads the rest of the report backwards — from what the data found to what an employer can do about it. Every recommendation below is attached to a specific finding from a specific page, and ordered by the strength of the evidence behind it. Where two pages point at the same move, the move appears once, with the strongest version of the case. The structure is deliberate: this is not a generic list of wellness priorities. It is the set of changes the 2026 data makes defensible, ranked by how cleanly the numbers support them.

The single thread running through almost all of it is the household. The policy is named for the employee, priced as an employee benefit, and reported to the board as headcount times cost-per-life. Underneath that framing sits a multigenerational population the screening infrastructure was never pointed at — and it is where both the health risk and the cost risk concentrate.

Screen the parent layer — it is both the sickest and the most expensive#

The cleanest finding in the report, on the strongest evidence, is also the one most employers act on least. The dependent layer — spouses, children, and parents on the policy — drives 66.5% of all claims and ₹217.4 Cr of incurred cost, more than twice the employee's ₹103.1 Cr. The parent layer alone is ₹118.2 Cr, the single largest block in the book. And at Enterprise tier the parent layer is 42.7% of the entire incurred bill.

The biomarker side is more nuanced than "dependents are sicker," and the nuance matters for where to spend. Hold age constant and most of the dependent glucose gap disappears — the dependent pool is older, not metabolically different at the same age. But two findings survive the age control. Anemia runs 14 to 20 percentage points higher in dependents at every working-age band. And the parent layer's cost is concentrated in two predictable, screenable conditions: cardiac admissions and orthopaedic fractures, which announce themselves years ahead of the admission.

Make HbA1c and a lipid panel a default, not an executive perk#

The most common metabolic findings in the report are also the cheapest to detect and the furthest upstream of the most expensive claims. 38.7% of HbA1c-tested professionals sit in the glucose-dysfunction band, essentially unchanged from 37.2% in 2025 on a sample four times the size. Scored honestly — a 50 mg/dL cutoff for women, 40 for men — three in five workers lack protective HDL. Two-thirds carry elevated LDL.

These are not findings that need an expensive test to surface. HbA1c, HDL, and LDL are routine lines on a panel most employers already run. The gap is that the panel is gated — by seniority, by age, and by income. A standard "executive health check from 40" rule misses every signal that peaks young: the 20s micronutrient deficits, the 30s liver and HDL strain, the male metabolic cluster that peaks in the 30s and 40s rather than the 50s.

The downstream cost is the reason this matters. Cardiac and circulatory admissions are the most expensive category in the book at ₹109,946 a claim, two-thirds of it parental — the endpoint of risk factors detectable two decades earlier. The free text underneath the structured claims keeps naming the same two conditions beneath the cardiac, renal, and stroke admissions: diabetes and hypertension. The early dysfunction the biomarker pages measure in the working-age employee is the comorbidity note on the parent's cardiac claim. They are one disease, observed at two points on a life.

Close the income-gated screening gap — a free benefit reaching half the workforce#

The most uncomfortable finding for any employer that already funds screening is that the benefit is being used backwards. Full-body diagnostic testing runs 15.6% among workers earning under ₹3 lakh and 54.3% among those above ₹40 lakh — a 3.5× gap on identical employer cover. The gradient holds inside a single job function: among engineers alone, screening climbs from 14.3% at the lowest income band to 61.5% at the highest. And the people the test is designed to catch screen the least — among workers with no diagnosed condition, only 21.4% tested last year, against 36.0% of the already-diagnosed. Testing follows the diagnosis instead of preceding it.

Only 24.3% of the workforce had a full-body panel last year, and 42.3% took no preventive action at all. The cover is built for early detection. The behaviour delivers late confirmation.

The lower bands are not refusing the test. They are not initiating it — and the barriers that fall hardest on them are lost wages and travel time, not the cost of the test itself, which the employer already pays.

Build the callback workflow — the bottleneck is follow-up, not the test#

A screening result that produces only a PDF in a phone changes nothing. This is the failure mode every biomarker page in the report converges on, and it is why a screening programme can run at high participation and still move no outcomes. The cheapest deficiencies in the dataset — vitamin D at 81.4% below sufficiency, B12 at 69.6% — are invisible without the test and trivially correctable after it, but only if a clinician closes the loop with a therapeutic dose and a re-test. A supplement aisle suggestion does not correct an established deficiency.

The pattern repeats across every marker: the finding is cheap to detect, cheap to fix, and currently lost in the gap between the test and the follow-up.

Design the plan around the household and the friction it actually meets#

Even when a claim is valid and paid, the household carries friction the cost report never shows. Of every ₹100 billed against the policy, ₹20.90 is deducted before the insurer pays — ₹98.1 Cr shaved off ₹470.2 Cr in the latest twelve months. Two-thirds of claims carry at least one deduction. And the friction is not fraud or denial: outright exclusions are under 2% of deducted rupees. The bulk is benefit-design mechanics — consumables, copay, and the room-rent-linked proportionate cut — all of which are decided at plan-design and at admission, not at the discharge desk.

The friction falls unevenly. The reimbursement household loses 24.9% to deduction against 18.0% for cashless, fronts the bill, and waits weeks for settlement. The biggest hospitalisations are cut the hardest — 32.4% on a claim above ₹5 lakh, an average ₹2.68 lakh out of pocket on the admissions that hurt a household most.

Maternity is the clearest case of a predictable cost left to friction. It is the largest claim line by volume in the working-age layers, scheduled nine months ahead, and yet it carries a higher out-of-pocket bite than the average claim — 27.9% deducted, mostly to sub-limits set below the real cost of a metro delivery. 73.4% of recorded deliveries are caesarean, three times the WHO ceiling, and a caesarean costs the policy 36% more than a vaginal birth.

What to track, what to ask, what to stop doing#

The recommendations above share a structure: the data already names the lever, and the employer already owns the tool. What is usually missing is the question that surfaces it. Three are worth adding to every annual review.

And two habits to retire. Stop gating screening by age and seniority — every band is the sickest band for something, and an age rule is built to miss what peaks young. And stop reading the claims book by volume alone — a year-end review ranked by count surfaces fever and routine admissions and misses the eight categories that drive two-thirds of spend. Ask which categories cost the most, not which occurred the most.